| Year |
Citation |
Score |
| 2023 |
Ragnhildstveit A, Khan R, Seli P, Bass LC, August RJ, Kaiyo M, Barr N, Jackson LK, Gaffrey MS, Barsuglia JP, Averill LA. 5-MeO-DMT for post-traumatic stress disorder: a real-world longitudinal case study. Frontiers in Psychiatry. 14: 1271152. PMID 38076677 DOI: 10.3389/fpsyt.2023.1271152 |
0.313 |
|
| 2023 |
Ragnhildstveit A, Roscoe J, Bass LC, Averill CL, Abdallah CG, Averill LA. The potential of ketamine for posttraumatic stress disorder: a review of clinical evidence. Therapeutic Advances in Psychopharmacology. 13: 20451253231154125. PMID 36895431 DOI: 10.1177/20451253231154125 |
0.319 |
|
| 2022 |
Abdallah CG, Roache JD, Gueorguieva R, Averill LA, Young-McCaughan S, Shiroma PR, Purohit P, Brundige A, Murff W, Ahn KH, Sherif MA, Baltutis EJ, Ranganathan M, D'Souza D, Martini B, et al. Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 35046508 DOI: 10.1038/s41386-022-01266-9 |
0.315 |
|
| 2020 |
Averill LA, Fouda S, Murrough JW, Abdallah CG. Chronic stress pathology and ketamine-induced alterations in functional connectivity in major depressive disorder: An abridged review of the clinical evidence. Advances in Pharmacology (San Diego, Calif.). 89: 163-194. PMID 32616206 DOI: 10.1016/Bs.Apha.2020.04.003 |
0.334 |
|
| 2019 |
Abdallah CG, Roache JD, Averill LA, Young-McCaughan S, Martini B, Gueorguieva R, Amoroso T, Southwick SM, Guthmiller K, López-Roca AL, Lautenschlager K, Mintz J, Litz BT, Williamson DE, Keane TM, et al. Repeated ketamine infusions for antidepressant-resistant PTSD: Methods of a multicenter, randomized, placebo-controlled clinical trial. Contemporary Clinical Trials. PMID 30999057 DOI: 10.1016/J.Cct.2019.04.009 |
0.301 |
|
| Show low-probability matches. |